BidaskClub upgraded shares of Genomic Health, Inc. (NASDAQ:GHDX) from a sell rating to a hold rating in a research report sent to investors on Saturday morning.

A number of other research analysts have also recently commented on GHDX. Canaccord Genuity reduced their price objective on Genomic Health from $36.00 to $35.00 and set a buy rating on the stock in a research note on Tuesday, August 15th. Piper Jaffray Companies restated a hold rating and set a $31.00 price objective on shares of Genomic Health in a research note on Thursday, August 3rd. Jefferies Group LLC restated a hold rating and set a $33.00 price objective on shares of Genomic Health in a research note on Monday, June 12th. Zacks Investment Research lowered Genomic Health from a hold rating to a sell rating in a research report on Tuesday, August 1st. Finally, Raymond James Financial, Inc. reaffirmed a market perform rating on shares of Genomic Health in a research report on Wednesday, May 3rd. They noted that the move was a valuation call. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the stock. The company has a consensus rating of Hold and a consensus target price of $32.00.

Genomic Health (NASDAQ:GHDX) opened at 30.77 on Friday. The company’s market capitalization is $1.07 billion. The stock’s 50 day moving average price is $31.54 and its 200-day moving average price is $31.34. Genomic Health has a 52-week low of $25.66 and a 52-week high of $33.97.

Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings data on Tuesday, August 1st. The medical research company reported ($0.08) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.06) by $0.02. The company had revenue of $85.50 million for the quarter, compared to analyst estimates of $86.08 million. Genomic Health had a negative return on equity of 4.33% and a negative net margin of 1.50%. The company’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.18) EPS. Analysts predict that Genomic Health will post ($0.01) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was first posted by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.dailypolitical.com/2017/08/29/genomic-health-inc-ghdx-upgraded-at-bidaskclub.html.

In other news, insider Phillip G. Febbo sold 3,174 shares of Genomic Health stock in a transaction dated Wednesday, July 19th. The stock was sold at an average price of $33.57, for a total transaction of $106,551.18. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Kimberly J. Popovits sold 5,000 shares of Genomic Health stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $32.32, for a total value of $161,600.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 42,642 shares of company stock worth $1,356,731. Corporate insiders own 46.20% of the company’s stock.

A number of hedge funds have recently made changes to their positions in GHDX. Wetherby Asset Management Inc. raised its stake in shares of Genomic Health by 3.7% in the second quarter. Wetherby Asset Management Inc. now owns 8,912 shares of the medical research company’s stock valued at $290,000 after buying an additional 317 shares in the last quarter. Dubuque Bank & Trust Co. raised its stake in shares of Genomic Health by 8.4% in the second quarter. Dubuque Bank & Trust Co. now owns 4,897 shares of the medical research company’s stock valued at $159,000 after buying an additional 379 shares in the last quarter. Parametric Portfolio Associates LLC raised its stake in shares of Genomic Health by 5.8% in the second quarter. Parametric Portfolio Associates LLC now owns 8,051 shares of the medical research company’s stock valued at $262,000 after buying an additional 441 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Genomic Health by 0.6% in the first quarter. Bank of New York Mellon Corp now owns 88,577 shares of the medical research company’s stock valued at $2,789,000 after buying an additional 500 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Genomic Health by 3.4% in the second quarter. The Manufacturers Life Insurance Company now owns 15,857 shares of the medical research company’s stock valued at $516,000 after buying an additional 520 shares in the last quarter. 88.91% of the stock is owned by hedge funds and other institutional investors.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Analyst Recommendations for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.